NCT03235687Unknown不适用
A Prospective, Randomized Blinded, Shared Decision Impact Trial of the ExoDx Prostate (IntelliScore), EPI Test, in Men Presenting for Initial Biopsy.
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 1,000
- 试验地点
- 2
- 主要终点
- Evaluate performance of the ExoDx Prostate(IntelliScore)
研究概览
简要总结
The purpose of this research study is to investigate the utility of a validated urine test which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy.
详细描述
Primary Objective(s)
- Evaluate performance of the ExoDx Prostate(IntelliScore) (EPI) to reduce the number of initial prostate biopsies by greater than or equal to 15% for men with an elevated Prostate-Specific Antigen 2-10ng/mL presenting for a biopsy in consultation with their urologist.
- Compare performance of both the ExoDx Prostate(IntelliScore) 15.6 and 20 cut-points with respect to the biopsy decision process.
- Assess physician satisfaction with the ExoDx Prostate(IntelliScore) report including test result presentation, graphics and interpretation.
- Assess urologist / patient satisfaction for ease of understanding test results and role on biopsy decision process.
Secondary Objectives
- Determine the medical economic impact of the ExoDx Prostate(IntelliScore) test in the prostate biopsy decision process.
- Correlation of the ExoDx Prostate(IntelliScore) score with the actual biopsy result by utilizing the Receiver Operating Characteristic of the Area Under Curve for discriminating high-grade (greater than or equal to Gleason Score 7, International Society of Urological Pathology 2 and 3) from low-grade (Gleason Score 6, International Society of Urological Pathology 1) and benign disease on initial prostate needle biopsy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •50 years of age
- •Clinical suspicion for prostate cancer
- •Elevated Prostate-specific antigen between: 2.0 - 10 ng/ mL
- •No clinical history of a prior negative biopsy
排除标准
- •History of prior prostate biopsy.
- •Use of medications or hormones that are known to affect serum Prostate-specific antigen levels within 3-6 months of study enrollment.
- •Clinical symptoms of urinary tract infection (including prostatitis) at the time of enrollment.
- •History of prostate cancer.
- •History of invasive treatments for benign prostatic hypertrophy (Benign Prostatic Hyperplasia) or lower urinary track symptoms within 6 months of study enrollment.
- •Known hepatitis (all types) and/or HIV documented in patient's medical record.
- •Patients with history of concurrent renal/bladder tumors.
结局指标
主要结局
Evaluate performance of the ExoDx Prostate(IntelliScore)
时间窗: 6 Months
Evaluate performance of the ExoDx Prostate(IntelliScore) to reduce the number of initial prostate biopsies by greater than or equal to 15% for men with an elevated prostate specific antigen between 2-10ng/mL presenting for a biopsy in consultation with their urologist.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral ResectionNon Muscle Invasive Bladder CancerNCT06287541The First Affiliated Hospital with Nanjing Medical University428
已完成
不适用
Evaluation of Urine Leakage of New Absorbing Incontinence Products in a Home Care EnvironmentUrinary IncontinenceNCT05484388Essity Hygiene and Health AB84
已完成
不适用
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)Non-muscle Invasive Bladder CancerNCT06126796Mayo Clinic107
招募中
不适用
Clinical study to evaluate the usefulness of urine heat shock protein 90 as a biomarker for acute allograft rejection after kidney transplantatioChronic kidney disease post kidney transplantationJPRN-UMIN000034082Department of Urology, Sapporo Medical University Schoo; of Medicine100
暂停
不适用
Patient Satisfaction of Virtual vs In-Person Workup and Treatment of Lower Urinary Tract Symptoms.Urologic DiseasesNCT05508165Indiana University60